Cellular Dynamics International: Top Innovative Company in Biomedicine

Reading time: 2 – 3 minutes

Cellular Dynamics International is one of 10 biomedicine companies included in Technology Review’s 50 Most Innovative Companies (TR50) for 2012 [1].

Cellular Dynamics International


What is a TR50 company? It is a business whose innovations force other businesses to change their strategic course. TR50 companies are nominated by Technology Review’s editors who look for companies that, over the last year, have demonstrated original and valuable technology, are bringing that technology to market at a significant scale, and are clearly influencing their competitors.

iPS Cells Inc., founded in 2004, changed its name to Cellular Dynamics International, Inc. in July 2008. Based in Madison, Wisconsin, Cellular Dynamics International, Inc. develops stem cell technologies for drug development and personalized medicine applications. It offers drug screening and toxicity testing products based on induced pluripotent stem (iPS) cell technology. The company also provides cardiac toxicity drug testing services, including GLP and non-GLP hERG electrophysiological assays, as well as action potential and cytotoxicity screens using cardiomycytes. In addition, it offers pluripotent stem cell derived products, including cardiomyocytes, hematopoietic cells, neural cells, and hepatocytes.

Cellular Dynamics International has a product line derived from iPS cells that is meant for use in targeted drug discovery, tissue regeneration, and life science research. The company was chosen to be a TR50 company because the use of human iPS cells in drug screening could accelerate the development of new therapies.

Interested in other Top Innovative Companies in Biomedicine? Check them all out with the tag Top Innovative Companies in Healthcare.

References

  1. The 50 Most Innovative Companies in 2012. Technology Review. Accessed 2012 Apr 10.
About the Author

Walter Jessen, Ph.D. is a Data Scientist, Digital Biologist, and Knowledge Engineer. His primary focus is to build and support expert systems, including AI (artificial intelligence) and user-generated platforms, and to identify and develop methods to capture, organize, integrate, and make accessible company knowledge. His research interests include disease biology modeling and biomarker identification. He is also a Principal at Highlight Health Media, which publishes Highlight HEALTH, and lead writer at Highlight HEALTH.